Current Hematologic Malignancy Reports

, Volume 1, Issue 4, pp 220–229 | Cite as

The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma

  • Elizabeth NaparstekEmail author


The addition of rituximab to chemotherapy has substantially changed the treatment strategies for patients with B-cell lymphomas. Rituximab, combined with standard chemotherapy regimens, shows consistently improved results compared with chemotherapy alone and has been extensively employed in both newly diagnosed and relapsed patients with B-cell lymphoma. Because of its low toxicity profile and its potent antilymphoma activity mediated through direct apoptotic and indirect effector mechanisms, rituximab also has been actively incorporated into stem cell transplantation (SCT) protocols to attain a state of minimal disease, provide a safe and effective method for in vivo purging prior to autologous SCT, and promote graft-versus-lymphoma effects in allogeneic SCT. This review compiles the still immature but rapidly growing data on this combined modality.


Overall Survival Stem Cell Transplantation Follicular Lymphoma Mantle Cell Lymphoma Autologous Stem Cell Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hahn T, Wolff SN, Czuczman M, et al.: ASBMT position statement. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2003, 9:667. Guidelines and position statement from the American Society for Blood and Marrow Transplantation (ASBMT) on the role of autologous transplantation in large-cell B-cell lymphoma.PubMedCrossRefGoogle Scholar
  2. 2.
    Vose JM, Rizzo DJ, Tao-Wu J, et al.: Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004, 10:116–127.PubMedCrossRefGoogle Scholar
  3. 3.
    Van Besien K: The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 2006, 20:235–244. The most up-to-date and comprehensive review on hematopoietic stem cell transplantation (SCT) in follicular lymphoma.PubMedCrossRefGoogle Scholar
  4. 4.
    Lenz G, Dreyling M, Schiegnitz E, et al.: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:2667–2674.PubMedCrossRefGoogle Scholar
  5. 5.
    Deconinck E, Foussard C, Milpied N, et al.: High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005, 105:3817–3823.PubMedCrossRefGoogle Scholar
  6. 6.
    Schouten HC, Qian W, Kvaloy S, et al.: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003, 21:3918–3927. Report of a randomized trial sponsored by the European Bone Marrow Transplant Registry (EBMTR), comparing conventional chemotherapy with autologous SCT (using unpurged or purged autografts) and demonstrating that autologous SCT prolongs progression-free and overall survival and showing no clear benefit for purging.PubMedCrossRefGoogle Scholar
  7. 7.
    Kiss TL, Mollee P, Lazarus HM, Lipton JH: Stem cell transplantation in mantle cell lymphoma: if, when and how? Bone Marrow Transplant 2005, 36:655–661. An updated and comprehensive review on hematopoietic SCT in mantle cell lymphoma.PubMedCrossRefGoogle Scholar
  8. 8.
    Grigg A, Ritchie D: Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004, 10:579–590. Summary of the current clinical evidence on graft-versus-lymphoma effects.PubMedCrossRefGoogle Scholar
  9. 9.
    Van Besien K, Loberiz FE, Bajorunaite R, et al.: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 10:3521–3529.CrossRefGoogle Scholar
  10. 10.
    Morris EM, Mackinnon S: Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin’s lymphoma. Best Pract Res Clin Haematol 2005, 18:129–142. The most recent and excellent review on reduced-intensity regimens in allogeneic stem cell transplantation in lymphoma.PubMedCrossRefGoogle Scholar
  11. 11.
    Buske C, Weigert O, Dryling M, et al.: Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006, 91:104–112. The most up-to-date and comprehensive review on the role of rituximab in the treatment of follicular lymphoma.PubMedGoogle Scholar
  12. 12.
    Feugier P, Van Hoof A, Sebban C, et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005, 23:4117–4126. Long-term follow-up of the original GELA study, further confirming that the addition of rituximab to a standard CHOP regimen significantly improves the survival of elderly patients with diffuse large B-cell lymphoma (DLBCL), thus substantiating R-CHOP as the standard therapy for this disease.PubMedCrossRefGoogle Scholar
  13. 13.
    Pfreundschuh M, Trumper L, Osterborg A, et al.: CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379–391. Large international study confirming that in patients below the age of 60 years with DLBCL, the addition of rituximab to CHOP and other more intensified regimens significantly improves disease-free and overall survival, providing the best results ever reported for this group of patients. This study also shows that intensifying chemotherapy while using rituximab produces no benefit.PubMedCrossRefGoogle Scholar
  14. 14.
    Kewalramani T, Zelenetz AD, Nimer SD, et al.: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004, 103:3684–3688.PubMedCrossRefGoogle Scholar
  15. 15.
    Lenz G, Dreyling M, Hoster E, et al.: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984–1992.PubMedCrossRefGoogle Scholar
  16. 16.
    Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013–7023. Prospective phase II trial showing the best treatment results for newly diagnosed mantle cell lymphoma.PubMedCrossRefGoogle Scholar
  17. 17.
    Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359–7368.PubMedCrossRefGoogle Scholar
  18. 18.
    Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al.: Molecular response assessed by PCR is the most important factor predicting failure free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 2000, 11:137–140.PubMedCrossRefGoogle Scholar
  19. 19.
    Jacobsen E, Freedman A: B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol 2004, 5:711–717. Comprehensive review on purging in lymphoma.PubMedCrossRefGoogle Scholar
  20. 20.
    Ladetto M, Corradini P, Vallet S, et al.: High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002, 100:1559–1565.PubMedCrossRefGoogle Scholar
  21. 21.
    Buckstein IR, Imrie K, Spaner D, et al.: Stem cell function and engraftment is not affected by in vivo purging with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin’s lymphoma. Semin Oncol 1999, 26(suppl 14):115–122.PubMedGoogle Scholar
  22. 22.
    van Heeckeren WJ, Vollweiler J, Fu P, et al.: Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. Br J Haematol 2006, 132:42–55. Randomized study emphasizing the importance of purging in follicular lymphoma.PubMedCrossRefGoogle Scholar
  23. 23.
    Galimberti S, Guerrini F, Morabito F, et al.: Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by rituximab. Bone Marrow Transplant 2003, 32:57–63. Prospective study evaluating the efficacy of in vivo purging with rituximab in advanced follicular lymphoma. This study also compares various PCR methods for the best and most accurate evaluation of the graft.PubMedCrossRefGoogle Scholar
  24. 24.
    Magni M, Di Nicola M, Devizzi L, et al.: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000, 96:864–869.PubMedGoogle Scholar
  25. 25.
    Gianni A, Magni M, Martelli M, et al.: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003, 102:749–755. Multicenter, prospective study demonstrating high response rates in newly diagnosed patients with mantle cell lymphoma using highdose sequential chemotherapy with rituximab for initial debulking and stem cell harvest to attain PCR negativity, with posttransplant consolidation for prolongation of complete remission and elimination of minimal residual disease.PubMedCrossRefGoogle Scholar
  26. 26.
    Lazzarino M, Arcaini L, Bernasconi P, et al.: A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002, 116:229–235.PubMedCrossRefGoogle Scholar
  27. 27.
    Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288–1294.PubMedCrossRefGoogle Scholar
  28. 28.
    Thieblemont C, Antal D, Lacotte-Thierry L, et al.: Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005, 104:1434–1441.PubMedCrossRefGoogle Scholar
  29. 29.
    Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event free survival and response duration compared with the standard weekly x4 schedule. Blood 2004, 103:4416–4423.PubMedCrossRefGoogle Scholar
  30. 30.
    Hoerr AL, Gao F, Hidalgo J, et al.: Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 2004, 22:4561–4566.PubMedCrossRefGoogle Scholar
  31. 31.
    Benekli M, Hahn T, Sha. F, et al.: Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin’s lymphoma patients. Bone Marrow Transplant 2003, 32:139–143.PubMedCrossRefGoogle Scholar
  32. 32.
    Khouri IF, Saliba RM, Hosing C, et al.: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2005, 23:2240–2247. The first study suggesting that the addition of rituximab before and after conventional SCT is associated with superior results in patients with aggressive B-cell non-Hodgkin’s lymphoma. The dose of rituximab used in this study was significantly higher than the dose commonly used.PubMedCrossRefGoogle Scholar
  33. 33.
    Brugger W, Hirsch J, Grunebach F, et al.: Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004, 15:1691–1698. A source of data on the ongoing effect of posttransplant rituximab in eliminating minimal residual disease after autologous SCT.PubMedCrossRefGoogle Scholar
  34. 34.
    Shimoni A, Hardan I, Avigdor A, et al.: Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high risk aggressive non Hodgkin’s lymphoma. Br J Haematol 2003, 122:457–464. First report on posttransplant anti-CD20 in allogeneic transplantation, discussing the benefits of rituximab in allogeneic SCT for lymphoma.PubMedCrossRefGoogle Scholar
  35. 35.
    Horwitz SM, Negrin RS, Blume KG, et al.: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004, 103:777–783.PubMedCrossRefGoogle Scholar
  36. 36.
    Neumann F, Harmsen S, Martin S, et al.: Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma. Ann Hematol 2006. Epub ahead of print.Google Scholar
  37. 37.
    Tsai DE, Moore HCF, Hardy CL, et al.: Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 1999, 24:521–526.PubMedCrossRefGoogle Scholar
  38. 38.
    Kewalramani T, Nimer SD, Zelenetz AD, et al.: Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin’s disease or aggressive non Hodgkin’s lymphoma. Bone Marrow Transplant 2003, 32:673–679.PubMedCrossRefGoogle Scholar
  39. 39.
    Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al.: Autotransplantation for advanced lymphoma and Hodgkin’s disease followed by post-transplant Rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002, 29:303–312.PubMedCrossRefGoogle Scholar
  40. 40.
    Olivieri A, Lucesole M, Capelli D, et al.: A new schedule of CHOP/rituximab plus granulocyte-macrophage colony stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:627–636.PubMedCrossRefGoogle Scholar
  41. 41.
    Selenko N, Maidic O, Draxier S, et al.: CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001, 15:1619–1626.PubMedCrossRefGoogle Scholar
  42. 42.
    Ho AYL, Devereux S, Mufti GJ, Pagliuca A: Reducedintensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. Bone Marrow Transplant 2003, 31:551–557.PubMedCrossRefGoogle Scholar
  43. 43.
    Khouri IF, Lee MS, Saliba RM, et al.: Nonablative stem cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407–4412. An important study showing significant improvement in the results of the reduced-intensity conditioning regimen in patients with advanced mantle cell lymphoma by the addition of high-dose rituximab, confirming the pivotal role of rituximab in combination with reduced-intensity regimens in B-cell lymphomas.PubMedCrossRefGoogle Scholar
  44. 44.
    Escalon MP, Champlin RE, Saliba RM, et al.: Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin’s lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004, 22:2419–2423.PubMedCrossRefGoogle Scholar
  45. 45.
    Mandigers CM, Verdonck LF, Meijerink JP, et al.: Graftversus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003, 32:1159–1163.PubMedCrossRefGoogle Scholar
  46. 46.
    Ratei R, Matylis A, Krahl D, et al.: Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8. Leuk Lymphoma 2000, 40:133–140.PubMedCrossRefGoogle Scholar
  47. 47.
    Ratanatharathorn V, Carson E, Reynolds C, et al.: Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000, 133:275–279.PubMedGoogle Scholar
  48. 48.
    Ratanatharathorn V, Ayash L, Reynolds C, et al.: Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505–511.PubMedCrossRefGoogle Scholar
  49. 49.
    Cutler C, Miklos D, Kim HT, et al.: Rituximab for steroidrefractory chronic graft-versus-host disease. Blood 2006, 108:756–762. The largest phase I/II study assessing the potential role of rituximab in the treatment of chronic GVHD, underlying possible new mechanisms.PubMedCrossRefGoogle Scholar
  50. 50.
    Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al.: Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004, 104:2603–2606.PubMedCrossRefGoogle Scholar
  51. 51.
    Okamoto M, Okano A, Akamatsu S, et al.: Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006, 20:172–173.PubMedCrossRefGoogle Scholar
  52. 52.
    Raj K, Narayanan S, Augustson B, et al.: Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 35:299–301.PubMedCrossRefGoogle Scholar
  53. 53.
    Corti P, Bonanomi S, Vallinoto C, et al.: Rituximab for immune hemolytic anaemia following T and B cell depleted hematopoietic stem cell transplantation. Acta Haematol 2003, 109:43–45.PubMedCrossRefGoogle Scholar
  54. 54.
    Hongeng S, Tardtong P, Worapongpaiboon S, et al.: Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant 2002, 29:871–872.PubMedCrossRefGoogle Scholar
  55. 55.
    Maschan AA, Skorobogatova EV, Balashov DN, et al.: Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant 2002, 30:405–407.PubMedCrossRefGoogle Scholar
  56. 56.
    Zhu K, Chen J, Chen S: Treatment of Epstein-Barr virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with rituximab following unrelated cord blood transplantation: a case report and literature review. Haematology 2005, 10:365–370.CrossRefGoogle Scholar
  57. 57.
    Badros A, Tricot G, Toor A, et al.: ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002, 42:205–209.PubMedCrossRefGoogle Scholar
  58. 58.
    Sorà F, De Matteis S, Piccirillo N, et al.: Rituximab for pure red cell aplasia after ABO mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005, 45:643–645.PubMedCrossRefGoogle Scholar
  59. 59.
    Milpied N, Vasseur B, Parquet N, et al.: Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000, 11(suppl 1):113–116.PubMedCrossRefGoogle Scholar
  60. 60.
    Weinstock DM, Ambrossi GG, Brennan C, et al.: Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006, 37:539–546. Comprehensive review summarizing the current methods for screening and for diagnosis of EBV-related post-transplant lymphoproliferative disorder, discussing the value of preemptive therapy with rituximab.PubMedCrossRefGoogle Scholar
  61. 61.
    Flinn IW, O’Donnel PV, Goodrich A, et al.: Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2000, 6:628–632.PubMedCrossRefGoogle Scholar
  62. 62.
    Voso MT, Pantel G, Weis M, et al.: In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/ mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lymphoma. Br J Haematol 2000, 109:729–735.PubMedCrossRefGoogle Scholar
  63. 63.
    Joyce RM, Regan M, Ottaway J, et al.: A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin’s lymphoma prior to and after highdose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Ann Oncol 2003, 14(suppl 1):i21-i27.PubMedCrossRefGoogle Scholar
  64. 64.
    Cairolli R, Grillo G, Tedeschi A, et al.: High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004, 89:361–362.Google Scholar
  65. 65.
    Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A: Rituximab-associated immune myelopathy. Blood 2003, 102:1557–1558.PubMedCrossRefGoogle Scholar
  66. 66.
    Ladetto M, Zallio F, Vallet S, et al.: Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin’s lymphoma. Leukemia 2001, 15:1941–1949.PubMedGoogle Scholar
  67. 67.
    Mangel J, Leitch H, Connors J, et al.: Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004, 15:283–290. Prospective study showing the advantage of adding rituximab to the pretransplant conditioning in patients with newly diagnosed mantle cell lymphoma, demonstrating a superior outcome when compared with matched-paired historical controls.PubMedCrossRefGoogle Scholar
  68. 68.
    Flohr T, Hess G, Kolbe K, et al.: Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002, 29:769–775.PubMedCrossRefGoogle Scholar
  69. 69.
    Hagberg H, Gisselbrecht C; CORAL Study Group: Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006, 17(suppl 4):iv31-iv32.PubMedCrossRefGoogle Scholar
  70. 70.
    Berinstein NL, Buckstein R, Imrie K, et al.: Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin’s lymphoma. Bone Marrow Transplant 2002, 29(suppl 1), S14-S17.PubMedCrossRefGoogle Scholar
  71. 71.
    Arcaini L, Orlandi E, Alessandrino EP, et al.: A model of in vivo purging with rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004, 34:175–179.PubMedCrossRefGoogle Scholar
  72. 72.
    Endo T, Sato N, Mogi Y, et al.: Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant 2004, 33:703–707.PubMedCrossRefGoogle Scholar
  73. 73.
    Emmanouilides C, Lill M, Telatar M, et al.: Mitoxantrone/ ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma. Clin Lymphoma 2002, 3:111–116.PubMedCrossRefGoogle Scholar
  74. 74.
    Belhadj K, Delfau-Larue MH, Elgnaoui T, et al.: Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin’s lymphoma: a single institution study. Ann Oncol 2004, 15:504–510.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Department of Hematology and BMT, Tel Aviv Sourasky Medical Center, Sackler Faculty of MedicineTel Aviv UniversityTel-AvivIsrael

Personalised recommendations